Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade

Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade Introduction

Milatuzumab Biosimilar is a monoclonal antibody (mAb) that targets the CD74 protein. It is a biosimilar version of the original Milatuzumab, which was developed and approved for clinical use in the treatment of B-cell malignancies. The biosimilar version has been designed to have the same structure, activity, and therapeutic potential as the original, but at a more affordable cost for research purposes.

Structure

Milatuzumab Biosimilar is a humanized IgG1 kappa monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a constant region (Fc) and a variable region (Fab), with the Fab region responsible for binding to the CD74 protein.

Activity

The main activity of Milatuzumab Biosimilar is its ability to bind to the CD74 protein. CD74 is a cell surface protein that is overexpressed in various types of cancer, including B-cell malignancies. By binding to CD74, Milatuzumab Biosimilar can block its activity and inhibit the growth and survival of cancer cells. It can also trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further enhance its anti- cancer effects.

Application

Milatuzumab Biosimilar has a wide range of potential applications in cancer research. It can be used as a tool for studying the role of CD74 in cancer development and progression. It can also be used to screen for potential therapeutic targets and to evaluate the efficacy of novel anti- cancer drugs. Additionally, Milatuzumab Biosimilar can be used in pre-clinical studies to assess its potential as a therapeutic agent for B-cell malignancies and other CD74-expressing cancers.

Therapeutic Target

The main therapeutic target of Milatuzumab Biosimilar is the CD74 protein. CD74 is a transmembrane protein that is involved in various cellular processes, including immune response, cell proliferation, and survival. It is overexpressed in many types of cancer and has been identified as a potential therapeutic target for cancer treatment. By targeting CD74, Milatuzumab Biosimilar can disrupt the signaling pathways that promote cancer cell growth and survival, leading to tumor regression and improved patient outcomes.

Conclusion

Milatuzumab Biosimilar is a promising research tool for studying the role of CD74 in cancer and evaluating its potential as a therapeutic target. Its similar structure and activity to the original Milatuzumab make it a cost-effective option for pre-clinical studies. With its ability to inhibit cancer cell growth and trigger immune-mediated cytotoxicity, Milatuzumab Biosimilar has the potential to be a valuable addition to the arsenal of anti- cancer therapies.